| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY 364947 (CAS 396129-53-6) is a chemical compound known as an inhibitor of MLTK, effectively obstructing the activity of the MLTK enzyme. Its role as an MLTK inhibitor can modulate specific cellular processes and signaling pathways, making it valuable for various research purposes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Another MEK1/2 inhibitor used for metastatic melanoma with specific BRAF mutations, as well as non-small cell lung cancer. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Another MEK inhibitor used in combination with encorafenib for certain types of melanoma. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
A MEK inhibitor being investigated for various cancers, including neurofibromatosis type 1-related tumors and uveal melanoma. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
An ERK1/2 inhibitor studied for its potential in impacting RAS/RAF-mutant cancers. | ||||||
Ulixertinib | 869886-67-9 | sc-507296 | 10 mg | $176.00 | ||
A potent and selective ERK1/2 inhibitor undergoing research and early-phase evaluations. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
A dual MEK and MLK inhibitor with potential antitumor activity. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
An investigational pan-RAF kinase inhibitor, which affects both wild-type and mutant RAF proteins. | ||||||